Abstract Library

#2734 Therapy-Related Myeloid Neoplasms in Patients with Neuroendocrine Neoplasms after Peptide Receptor Radionuclide Therapy: A Systematic Review

Introduction: Therapy-related myeloid neoplasm (t-MN) has been reported as a potential long-term and frequently lethal adverse event after PRRT in NET. However, the incidence, time of diagnosis, and nature of t-MN is unclear.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sonbol M

Authors: Sonbol M, Hilal T, Halfdanarson T,

Keywords: PRRT, t-MN, therapy-related myeloid neoplasm, leukemia, NET, MDS,

#2190 A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors

Introduction: Retrospective studies showed that changes in plasma chromogranin A (CgA) might predict change in tumor burden in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Dam G, Grønbæk H, Sørbye H, Thiis-Evensen E, Paulsson B,

Keywords: gep-net, ct, cga, correlation,

#1841 The Characteristics and Survivals of Gastrointestinal Neuroendocrine Tumors, A Single Center Experience from Developing Country

Introduction: Gastrointestinal neuroendocrine tumors (GINETs) are a heterogeneous group of tumors with variable behaviors. We analyzed baseline characteristics and outcomes of GINETs and impact of the tumor grade on the overall survival.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Ali J, Qubtia M, Hassan A, Ahmad U,

Keywords: Neuroendocrine tumors, retrospective studies,

#1125 Efficacy of PRRT in Metastatic Neuroendocrine Tumors; A Retrospective Large Single Institutional Study

Introduction: PRRT is a well-documented and well-established treatment for metastatic neuroendocrine tumours. However retrospective studies detailing the efficacy of PRRT are lacking.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Jan H

Authors: Jan H, Wyld D, Burge M,

Keywords: lutetium, somatostatin receptor, PRRT, neuroendocrine tumors,

#1072 Predictive Factors for Antiproliferative Activity of Octreotide LAR in Advanced Neuroendocrine Tumors

Introduction: The antiproliferative activity of Octreotide LAR in Neuroendocrine Tumors(NETs) has been demonstrated by small retrospective studies and confirmed by a prospective phase III trial(PROMID).However,there are limited data about the duration and predictors of response.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Toumpanakis C

Authors: Toumpanakis C, Laskaratos F, Maragkoudakis E, Naik K, Oikonomopoulos N,

Keywords: octreotide LAR, NETs,